Cohance Lifesciences Limited operates across pharmaceutical contract development and manufacturing, active pharmaceutical ingredients, formulations, and related healthcare products. Its businesses serve global pharmaceutical customers and benefit from outsourcing trends in the healthcare industry. Diversification across pharmaceutical manufacturing and specialized products can reduce dependence on individual markets. Increasing outsourcing by global pharmaceutical companies provides long-term growth opportunities. Regulatory compliance, customer concentration, product approvals, manufacturing costs, and international pharmaceutical demand remain important considerations.
| Market cap | Sales (TTM) | Net profit (TTM) | P/E | EPS (TTM) | P/B | ROE | ROCE | Debt / equity | Free cash flow | EV / EBITDA | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹17,512 cr | ₹2,691 cr | ₹105 cr | 112.7 | 4.06 | 4.48 | 6.4% | 8.0% | 0.04 | ₹169 cr | 41.4 | 0.86 |
| Quarter | Sales ₹ cr | Net profit ₹ cr | EPS | EPS YoY | Sales YoY | Net margin |
|---|---|---|---|---|---|---|
| Jun 2026 | 422 | -45 | -0.63 | -149.2% | -23.1% | -10.7% |
| Mar 2026 | 619 | 8 | 0.51 | -69.1% | +54.0% | 1.3% |
| Dec 2025 | 544 | 29 | 0.96 | -70.5% | +77.3% | 5.3% |
| Sep 2025 | 1,105 | 113 | 3.22 | -0.3% | +328.7% | 10.2% |
| Jun 2025 | 549 | 46 | 1.28 | -46.4% | +138.1% | 8.5% |
| Mar 2025 | 402 | 39 | 1.65 | — | — | 9.6% |
| Dec 2024 | 307 | 83 | 3.26 | +77.2% | +39.7% | 27.1% |
| Sep 2024 | 258 | 82 | 3.23 | +3.2% | +11.5% | 31.8% |
| Check | Result |
|---|---|
| Latest quarter EPS up 25%+ on a year ago | ✗ Fail |
| EPS growth accelerating over 3 quarters | ✗ Fail |
| Sales up 25%+, or sales growth accelerating | ✗ Fail |
| Annual EPS up 25%+ in each of the last 2 years | ✗ Fail |
| Net margin above the same quarter last year | ✗ Fail |
| Method | Checks | Score | Verdict |
|---|---|---|---|
| Minervini | ✓ Close above the 150- and 200-day averages ✓ 150-day above 200-day ✗ 200-day rising for a month ✓ 50-day above the 150- and 200-day ✓ Close above the 50-day ✓ At least 25% above the 52-week low · low 279.90 ✗ Within 25% of the 52-week high · high 904.75 ✗ RS percentile 70 or more · RS 17 Trend template - the gate, measured: a modest 21-day edge. | 5/8 | 5 of 8 |
| Weinstein | Stan Weinstein's stage analysis on the 30-week moving average. | Stage 2 - advancing | |
| CAN SLIM | ✗ C latest quarter EPS up 25%+ ✗ A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✗ N within 15% of the 52-week high · high 904.75 ✓ S more volume on up days than down days (50 sessions) · 2.41x ✗ L RS percentile 80 or more · RS 17 — I institutional sponsorship rising · shareholding not collected yet ✓ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 45% William O'Neil's growth-leader checklist. | 2/6 | Weak |
| Darvas | ✗ New 52-week high in the last 120 sessions Darvas needs a new 52-week high to start a box. | 10/100 | No box |
| Turtle | ✗ Close above the prior 55-session high · 484.00 ✗ Close above the prior 20-session high · 482.25 ✗ Close below the prior 20-session low · 427.50 Donchian channel breakout - the Turtle traders' entry. | No signal | |
| Greenblatt | — Earnings yield (EBITDA / EV) · 2.4% — Return on capital (ROCE) · 8.0% Joel Greenblatt's Magic Formula: good businesses at good prices, ranked across all companies. Earnings yield uses EBITDA, as EBIT is not held separately. | 8/100 | Weak |
| Graham | ✗ Price at or below the Graham number · Graham number 96.61 ✗ P/E 15 or less · P/E 112.7 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 4.48 ✓ Current ratio 2 or more · 2.78 — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests. | 21/100 | Expensive |
| Piotroski | ✓ Profitable (ROA > 0) ✓ Operating cash flow positive ✗ ROA rising ✓ Cash flow above net profit (earnings quality) ✗ Long-term debt / assets falling ✓ Current ratio rising · 2.78 ✗ No new shares issued ✗ Margin rising (net margin) ✓ Asset turnover rising Joseph Piotroski's F-score, FY 2025 -> 2026. | 5/9 | Average |
| Stock | 1M % | 3M % | 6M % | 1Y % | 3Y % | 5Y % | P/E | P/B | ROE % | ROCE % | ROA % | D/E | EV/EBITDA | ₹ Cr | Sales TTM ₹ Cr | Profit TTM ₹ Cr | EPS | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COHANCE this stock | +4.5 | +1.6 | +24.0 | -48.6 | — | — | 112.7 | 4.48 | 6.4 | 8.0 | — | 0.04 | 41.4 | 17,512 | 2,691 | 105 | 4.1 | 0.86 |
| BLISSGVS | -8.0 | +29.9 | +147.2 | +312.3 | +606.5 | +476.9 | 48.7 | 5.57 | 11.5 | 16.8 | — | 0.00 | 29.3 | 6,650 | 1,005 | 142 | 12.9 | 1.10 |
| VENUSREM | +0.7 | -5.9 | +55.8 | +252.6 | +518.8 | +242.4 | 18.3 | 3.21 | 16.8 | 21.9 | — | 0.00 | 13.7 | 2,130 | 811 | 116 | 86.9 | 0.88 |
| INDSWFTLAB | -5.7 | +50.4 | +153.3 | +247.2 | +287.1 | +472.2 | 51.6 | 2.21 | 3.2 | 3.9 | — | 0.01 | 33.4 | 3,056 | 665 | 57 | 6.8 | 0.78 |
| MOREPENLAB | +0.5 | +108.6 | +194.2 | +152.6 | +242.7 | +132.7 | 47.5 | 5.34 | 7.9 | 10.1 | — | 0.16 | 40.2 | 6,657 | 1,951 | 140 | 2.6 | 1.46 |
| SHILPAMED | -14.2 | +40.1 | +113.1 | +146.1 | +421.3 | +189.7 | 57.3 | 6.61 | 9.8 | 11.4 | — | 0.25 | — | 17,130 | 1,682 | 297 | 15.3 | 0.87 |
| RUBICON | -15.1 | -1.7 | +60.3 | +140.3 | — | — | 83.8 | 19.08 | 22.4 | — | — | 0.20 | 61.3 | 24,587 | 1,936 | 288 | 17.7 | 0.34 |
| LAURUSLABS | +5.9 | +32.7 | +83.2 | +129.9 | +421.9 | +235.3 | 88.9 | 21.09 | 18.2 | 17.9 | — | 0.45 | 62.0 | 1.12L | 8,839 | 1,252 | 23.3 | 0.74 |
| ZIMLAB | +2.0 | +14.2 | +73.3 | +101.9 | +17.5 | — | 168.5 | 2.50 | 2.1 | 5.5 | — | 0.42 | 21.1 | 740 | 397 | 4 | 0.8 | 0.75 |
| ACUTAAS | -5.4 | -11.0 | +35.0 | +97.5 | — | — | 69.0 | 16.11 | 24.0 | 31.7 | — | 0.02 | 49.9 | 26,636 | 1,462 | 387 | 47.2 | 0.77 |
| IOLCP | -9.8 | +17.8 | +108.9 | +87.8 | +99.0 | +56.2 | 32.0 | 2.99 | 7.9 | 10.7 | — | 0.07 | 20.7 | 5,376 | 2,524 | 168 | 5.7 | 1.13 |